L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 532 ILS -4.52% Market Closed
Market Cap: 420.7m ILS

Wall Street
Price Targets

LCTX Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast LCTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LCTX is 1 297.48 ILS with a low forecast of 616.68 ILS and a high forecast of 2 884.97 ILS.

Lowest
Price Target
616.68 ILS
16% Upside
Average
Price Target
1 297.48 ILS
144% Upside
Highest
Price Target
2 884.97 ILS
442% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
CCCC
C4 Therapeutics Inc
390% Upside
300142
Walvax Biotechnology Co Ltd
37% Downside
DSGN
Design Therapeutics Inc
27% Upside
VNDA
Vanda Pharmaceuticals Inc
92% Upside
ZNTL
Zentalis Pharmaceuticals Inc
287% Upside
FOLD
Amicus Therapeutics Inc
59% Upside
IMMX
Immix Biopharma Inc
15% Upside
DTIL
Precision BioSciences Inc
564% Upside

Revenue
Forecast

Revenue Estimate
Lineage Cell Therapeutics Inc

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 58%.

6%
Past Growth
58%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Lineage Cell Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LCTX's stock price target?
Price Target
1 297.48 ILS

According to Wall Street analysts, the average 1-year price target for LCTX is 1 297.48 ILS with a low forecast of 616.68 ILS and a high forecast of 2 884.97 ILS.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
58%

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 58%.

Back to Top